MDMA’s Advice To FDA On 510(k) Reform: Tone It Down
This article was originally published in The Gray Sheet
Executive Summary
Rather than take on so much at once, FDA should focus its 510(k) reform efforts on a few initiatives that will have the most bang for the agency’s buck, Medical Device Manufacturers Association’s Mark Leahey says. MDMA’s suggestions? Implement the new “network of experts” program and risk-benefit guidance.
You may also be interested in...
A Long, Strange Trip: 510(k) Reform At One Year
A rundown by “The Gray Sheet” of the most significant 510(k) reform actions taken in 2011, what’s on deck for 2012 and what reform will mean to device makers in the near term.
Risk And Benefit, Quantified: CDRH Expands Use Of New Statistical Framework
Decision analysis tools will be put into practice as part of the device center’s priority “innovation pathway” for breakthrough devices and in a pilot program focused on obesity devices. The techniques may allow for shorter development and review cycles, among other benefits, CDRH says.
Device Makers Want A Spot In FDA’s New “Network Of Experts”
Device industry players argue FDA should expand its vision of the new network-of-experts program to include industry experts who may understand new technologies best. They also raise concerns about confidentiality protection and review delays in public comments to the agency on the new initiative.